Purespring Therapeutics
BioTech/Drugs - The London Bioscience Innovation Centre Londo, N/A, gb
Purespring Therapeutics Employees
Purespring Therapeutics Details
Purespring, which launched in November 2020 with £45 million of funding from Syncona Ltd, is the first company to be directly targeting the podocyte, a specialized kidney cell implicated in many kidney diseases, through AAV gene therapy. This approach is based on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases.
Website:
purespringtx.com
Employees:
20 - 49
HQ:
N/A
Location:
The London Bioscience Innovation Centre Londo, N/A, gb
Revenue:
2.5 - 5 Million
Purespring Therapeutics Technologies
Email Providers
Outlook
Load Balancers
Apache
CMS
WordPress.org
Tag Management
Google Tag Manager
Other
Mobile Friendly